文献检索，用中文搜 PubMed

Docetaxel (DTX) liposome powder was stable over three months, and the liposome suspension was stable within 8 h.2. Rabbits, rats and mice were intravenously treated with DTX-LP or with a DTX injection (DTX-IN). Four major metabolites of DTX were identified in feces: M1, M2, M3 and M4. However, M4 was not found in the bile.3. The most abundant metabolite in the feces was M2 followed by M1/M3, with only a small amount of M4 observed. The most abundant metabolite in bile was also M2, followed by M1/M3.4. The liposomal delivery of DTX did not alter the in vivo drug metabolism, and there were no significant differences among the three species tested. This suggested that this formulation is pharmaceutically safe for clinical use. In contrast to the traditional injected formula, DTX-LP administration significantly delayed drug metabolism, as observed in feces and bile. This property will greatly enhance the DTX therapeutic efficacy and reduce the systemic side effects of NSCLC treatment.

多西他赛（DTX）脂质体粉末在三个月内稳定，脂质体悬浮液在8小时内稳定。
对兔、大鼠和小鼠静脉注射DTX脂质体（DTX-LP）或多西他赛注射液（DTX-IN）。在粪便中鉴定出DTX的四种主要代谢物：M1、M2、M3和M4。然而，在胆汁中未发现M4。
粪便中含量最高的代谢物是M2，其次是M1/M3，仅观察到少量M4。胆汁中含量最高的代谢物也是M2，其次是M1/M3。
DTX的脂质体递送未改变体内药物代谢，在所测试的三个物种之间没有显著差异。这表明该制剂在临床上使用具有药学安全性。与传统注射剂型相比，DTX-LP给药显著延迟了药物代谢，在粪便和胆汁中均有观察到。这一特性将大大提高DTX的治疗效果，并降低非小细胞肺癌治疗的全身副作用。

Docetaxel (DTX) liposome powder was stable over three months, and the liposome suspension was stable within 8 h.2. Rabbits, rats and mice were intravenously treated with DTX-LP or with a DTX injection (DTX-IN). Four major metabolites of DTX were identified in feces: M1, M2, M3 and M4. However, M4 was not found in the bile.3. The most abundant metabolite in the feces was M2 followed by M1/M3, with only a small amount of M4 observed. The most abundant metabolite in bile was also M2, followed by M1/M3.4. The liposomal delivery of DTX did not alter the in vivo drug metabolism, and there were no significant differences among the three species tested. This suggested that this formulation is pharmaceutically safe for clinical use. In contrast to the traditional injected formula, DTX-LP administration significantly delayed drug metabolism, as observed in feces and bile. This property will greatly enhance the DTX therapeutic efficacy and reduce the systemic side effects of NSCLC treatment.

多西他赛（DTX）脂质体粉末在三个月内稳定，脂质体悬浮液在8小时内稳定。
对兔、大鼠和小鼠静脉注射DTX脂质体（DTX-LP）或多西他赛注射液（DTX-IN）。在粪便中鉴定出DTX的四种主要代谢物：M1、M2、M3和M4。然而，在胆汁中未发现M4。
粪便中含量最高的代谢物是M2，其次是M1/M3，仅观察到少量M4。胆汁中含量最高的代谢物也是M2，其次是M1/M3。
DTX的脂质体递送未改变体内药物代谢，在所测试的三个物种之间没有显著差异。这表明该制剂在临床上使用具有药学安全性。与传统注射剂型相比，DTX-LP给药显著延迟了药物代谢，在粪便和胆汁中均有观察到。这一特性将大大提高DTX的治疗效果，并降低非小细胞肺癌治疗的全身副作用。

Suppr 超能文献